Lipid-based nanocarriers for RNA delivery

Current Pharmaceutical Design

Volumn 21, Issue 22, 2015, Pages 3140-3147

  Xue, Hui Yi ^a   Guo, Pengbo ^a   Wen, Wu Cheng ^a   Wong, Ho Lun ^a  

^a TEMPLE UNIVERSITY   (United States)

Author keywords

Drug delivery; Lipid; Nanocarrier; RNA interference; Small interfering RNA

Indexed keywords

CATION; LIPOSOME; MACROGOL; POLYMER; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; DRUG CARRIER; LIPID; NANOMATERIAL; RNA;

ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; CLINICAL TRIAL (TOPIC); DRUG POTENCY; GENE SILENCING; HUMAN; LIPOSOMAL GENE DELIVERY SYSTEM; MOLECULARLY TARGETED THERAPY; NANOEMULSION; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; TOXICITY; CHEMISTRY; NANOMEDICINE; PROCEDURES; RNA INTERFERENCE; RNAI THERAPEUTICS;

DRUG CARRIERS; LIPIDS; NANOMEDICINE; NANOSTRUCTURES; RNA; RNA INTERFERENCE; RNAI THERAPEUTICS;

EID: 84938632589     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150531164540     Document Type: Article

References (69)

1. Kumar LD, Clarke AR. Gene manipulation through the use of small interfering RNA (siRNA): From in vitro to in vivo applications. Adv Drug Deliv Rev 2007; 59(2): 87-100.
2. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391(6669): 806-11.
3. Dogini DB, Pascoal VD, Avansini SH, Vieira AS, Pereira TC, Lopes-Cendes I. The new world of RNAs. Genet Mol Biol 2014; 37(1): 285-93.
4. Ipsaro JJ, Joshua-Tor L. From guide to target: molecular insights into eukaryotic RNA-interference machinery. Nat Struct Mol Biol 2015; 22(1): 20-8.
5. Mansoori B, Shotorbani SS, Baradaran B. RNA Interference and its Role in cancer therapy. Adv Pharm Bull 2014; 4(4): 313-21.
6. Kumar LD, Clarke AR. Gene manipulation through the use of small interfering RNA (siRNA): From in vitro to in vivo applications. Adv Drug Deliv Rev 2007; 59(2): 87-100.
7. Musacchio T, Torchilin VP. siRNA delivery: from basics to therapeutic applications. Front In Biosci 2012; 18: 58-79.
8. Seth S, Johns R, Templin MV. Delivery and biodistribution of siRNA for cancer therapy: challenges and future prospects. Ther Deliv 2012; 3(2): 245-61.
9. Oh Y-K, Park TG. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev 2009; 61(10): 850-62.
10. Kaur IP, Sharma G. siRNA: a new approach to target neuropathic pain. Biodrugs 2012; 26(6): 401-12.
11. Huda R, Tüzün E, Christadoss P. Complement C2 siRNA mediated therapy of myasthenia gravis in mice. J Autoimmun 2013; 42: 94-104.
12. Novobrantseva TI, Borodovsky A, Wong J, et al. Systemic RNAimediated gene silencing in nonhuman primate and rodent myeloid cells. Mol Ther Nucl Acids 2012; 1(1): e4.
13. Gavrilov K, Saltzman WM. Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med 2012; 85(2): 187.
14. Ma Z, Li J, He F, Wilson A, Pitt B, Li S. Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem Biophys Res Commun 2005; 330(3): 755-9.
15. Draz MS, Fang BA, Zhang P, et al. Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections. Theranostics 2014; 4(9): 872-92.
16. Pathak K, Keshri L, Shah M. Lipid nanocarriers: influence of lipids on product development and pharmacokinetics. Crit Rev Ther Drug Carrier Syst 2011; 28(4): 357-93.
17. Mallick S, Choi JS. Liposomes: versatile and biocompatible nanovesicles for efficient biomolecules delivery. J Nanosci Nanotechnol 2014; 14(1): 755-65.
18. Tagami T, Uehara Y, Moriyoshi N, Ishida T, Kiwada H. Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA. J Control Release 2011; 151(2): 149-54.
19. Bae KH, Lee JY, Lee SH, Park TG, Nam YS. Optically traceable solid lipid nanoparticles loaded with siRNA and paclitaxel for synergistic chemotherapy with in situ imaging. Adv Healthcare Mater 2013; 2(4): 576-84.
20. Chen Y, Bathula SR, Li J, Huang L. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem 2010; 285(29): 22639-50.
21. Yamada Y, Tabata M, Yasuzaki Y, et al. A nanocarrier system for the delivery of nucleic acids targeted to a pancreatic beta cell line. Biomaterials 2014; 35(24): 6430-8.
22. Souto E, Nayak A, Murthy R. Lipid nanoemulsions for anti-cancer drug therapy. Pharmazie Int J Pharm Sci 2011; 66(7): 473-8.
23. Brito LA, Chan M, Shaw CA, et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther 2014; 22(12): 2118-29.
24. Oh MH, Kim JS, Lee JY, Park TG, Nam YS. Radio-opaque theranostic nanoemulsions with synergistic anti-cancer activity of paclitaxel and Bcl-2 siRNA. RSC Adv 2013; 3(34): 14642-51.
25. Kaneda MM, Sasaki Y, Lanza GM, Milbrandt J, Wickline SA. Mechanisms of nucleotide trafficking during siRNA delivery to endothelial cells using perfluorocarbon nanoemulsions. Biomaterials 2010; 31(11): 3079-86.
26. Xue HY, Liu S, Wong HL. Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine. Nanomedicine 2014; 9(2): 295-312.
27. Simberg D, Weisman S, Talmon Y, Barenholz Y. DOTAP (and other cationic lipids): chemistry, biophysics, and transfection. Crit Rev Ther Drug Carrier Syst 2004; 21(4): 62.
28. Lappalainen K, Jääskeläinen I, Syrjänen K, Urtti A, Syrjänen S. Comparison of cell proliferation and toxicity assays using two cationic liposomes. Pharm Res 1994; 11(8): 1127-31.
29. Stoddart MJ. Cell viability assays: introduction. In: Stoddart MJ, Ed. Mammalian Cell Viability. USA: Humana Press 2011; pp. 1-6.
30. Wu J, Lizarzaburu ME, Kurth MJ, et al. Cationic lipid polymerization as a novel approach for constructing new DNA delivery agents. Bioconjug Chem 2001; 12(2): 251-7.
31. Aberle AM, Tablin F, Zhu J, Walker NJ, Gruenert DC, Nantz MH. A novel tetraester construct that reduces cationic lipid-associated cytotoxicity. Implications for the onset of cytotoxicity. Biochemistry 1998; 37(18): 6533-40.
32. Hollins AJ, Omidi Y, Benter IF, Akhtar S. Toxicogenomics of drug delivery systems: Exploiting delivery system-induced changes in target gene expression to enhance siRNA activity. J Drug Target 2007; 15(1): 83-8.
33. Zhang J-S, Liu F, Huang L. Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. Adv Drug Deliv Rev 2005; 57(5): 689-98.
34. Tousignant JD, Gates AL, Ingram LA, et al. Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid: plasmid DNA complexes in mice. Hum Gene Ther 2000; 11(18): 2493-513.
35. Tan Y, Huang L. Overcoming the inflammatory toxicity of cationic gene vectors. J Drug Target 2002; 10(2): 153-60.
36. Choi JS, Lee EJ, Jang HS, et al. New cationic liposomes for gene transfer into mammalian cells with high efficiency and low toxicity. Bioconjug Chem 2001; 12(1): 108-13.
37. Simões S, Filipe A, Faneca H, et al. Cationic liposomes for gene delivery. Expert Opin Drug Deliv 2005; 2(2): 237-54.
38. Song LY, Ahkong QF, Rong Q, et al. Characterization of the inhibitory effect of PEG-lipid conjugates on the intracellular delivery of plasmid and antisense DNA mediated by cationic lipid liposomes. Biochim Biophys Acta Biomembr 2002; 1558(1): 1-13.
39. Mishra S, Webster P, Davis ME. PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles. Eur J Cell Biol 2004; 83(3): 97-111.
40. Dams ETM, Laverman P, Oyen WJG, et al. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther 2000; 292(3): 1071-9.
41. Ishida T, Ichihara M, Wang XY, et al. Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release 2006; 112(1): 15-25.
42. Judge A, McClintock K, Phelps JR, et al. Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. Mol Ther 2006; 13(2): 328-37.
43. Lv H, Zhang S, Wang B, et al. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 2006; 114(1): 100-9.
44. Zhi DF, Zhang SB, Wang B, et al. Transfection efficiency of cationic lipids with different hydrophobic domains in gene delivery. Bioconjug Chem 2010; 21(4): 563-77.
45. Swami A, Goyal R, Tripathi SK, et al. Effect of homobifunctional crosslinkers on nucleic acids delivery ability of PEI nanoparticles. Int J Pharm 2009; 374(1): 125-38.
46. Breunig M, Lungwitz U, Liebl R, et al. Breaking up the correlation between efficacy and toxicity for nonviral gene delivery. Proc Natl Acad Sci USA 2007; 104(36): 14454-59.
47. Simberg D, Weisman S, Talmon Y, et al. DOTAP (and other cationic lipids): chemistry, biophysics, and transfection. Crit Rev Therap Drug Carrier Syst 2004; 21(4): 257-317.
48. Haque ME, McIntosh TJ, Lentz BR. Influence of lipid composition on physical properties and peg-mediated fusion of curved and uncurved model membrane vesicles: “Nature's own” fusogenic lipid bilayer. Biochemistry 2001; 40(14): 4340-8.
49. Nchinda G, Überla K, Zschörnig O. Characterization of cationic lipid DNA transfection complexes differing in susceptability to serum inhibition. BMC Biotech 2002; 2(1): 12.
50. Akinc A, Goldberg M, Qin J, et al. Development of lipidoid– siRNA formulations for systemic delivery to the liver. Mol Ther 2009; 17(5): 872-9.
51. Love KT, Mahon KP, Levins CG, et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA 2010; 107(5): 1864-69.
52. Jayaraman M, Ansell SM, Mui BL, et al. Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed 2012; 51(34): 8529-33.
53. Narvekar M, Xue HY, Eoh JY, et al. Nanocarrier for Poorly Water-Soluble Anticancer Drugs—Barriers of Translation and Solutions. AAPS PharmSciTech 2014; 1-12.
54. Xue HY, Wong HL. Tailoring nanostructured solid-lipid carriers for time-controlled intracellular siRNA kinetics to sustain RNAimediated chemosensitization. Biomater 2011; 32(10): 2662-72.
55. Xue HY, Wong HL. Solid lipid–PEI hybrid nanocarrier: an integrated approach to provide extended, targeted, and safer siRNA therapy of prostate cancer in an all-in-one manner. ACS Nano 2011; 5(9): 7034-47.
56. Xue HY, Narvikar M, Zhao JB, et al. Lipid encapsulation of cationic polymers in hybrid nanocarriers reduces their non-specific toxicity to breast epithelial cells. Pharm Res 2013; 30(2): 572-83.
57. Masotti A, Moretti F, Mancini F, et al. Physicochemical and biological study of selected hydrophobic polyethylenimine-based polycationic liposomes and their complexes with DNA. Bioorg Med Chem 2007; 15(3): 1504-15.
58. Ewe A, Aigne A. Nebulization of liposome–polyethylenimine complexes (lipopolyplexes) for DNA or siRNA delivery: Physicochemical properties and biological activity. Eur J Lipid Sci Technol 2014; 116: 1195-204.
59. Rossi JJ. RNAi therapeutics: SNALPing siRNAs in vivo. Gene Ther 2005; 13(7): 583-84.
60. Jeffs LB, Palmer LR, Ambegia EG, et al. A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA. Pharm Res 2005; 22(3): 362-72.
61. Barros SA, Gollob JA. Safety profile of RNAi nanomedicines. Adv Drug Deliv Rev 2012; 64(15): 1730-7.
62. Zimmermann TS, Lee ACH, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006; 441(7089): 111-4.
63. Tekmira Pharmaceuticals. Tekmira Pharmaceuticals completes ApoB SNALP Phase 1 clinical trial. [Posted 2010 Jan 7, Accessed 2013 Jun 20]. Available from: (http://investor.tekmirapharm.com/releasedetail.cfm?releaseid=534353)
64. Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Cancer Nanotechnol 2010; 624: 25-37.
65. Tamaru M, Akita H, Nakatani T, et al. Application of apolipoprotein E-modified liposomal nanoparticles as a carrier for delivering DNA and nucleic acid in the brain. Int J Nanomed 2014; 9: 4267.
66. Mokhtarieh AA, Cheong S, Kim S, et al. Asymmetric liposome particles with highly efficient encapsulation of siRNA and without nonspecific cell penetration suitable for target-specific delivery. Biochim Biophys Acta Biomembr 2012; 1818(7): 1633-41.
67. Okamoto A, Asai T, Kato H, et al. Antibody-modified lipid nanoparticles for selective delivery of siRNA to tumors expressing membrane-anchored form of HB-EGF. Biochem Biophys Res Commun 2014; 449(4): 460-5.
68. Asai T, Tsuzuku T, Takahashi S, et al. Cell-penetrating peptideconjugated lipid nanoparticles for siRNA delivery. Biochem Biophys Res Commun 2014; 444(4): 599-604.
69. Weyland M, Griveau A, Bejaud J, et al. Lipid nanocapsule functionalization by lipopeptides derived from human papillomavirus type-16 capsid for nucleic acid delivery into cancer cells. Int J Pharm 2013; 454(2): 756-64.